Sanofi's Q3 results are feeding fears that its innovation engine may not be able to outpace the decline in its aging diabetes unit.

On a day that Teva chairman Sol Barer described as “the beginning of the next chapter for our company,” all analysts got was more of the same.

Cost cuts are coming, and “rapidly,” Allergan execs said on Wednesday's Q3 earnings conference call.

Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.

Merck KGaA and South Korea’s Samsung BioLogics are deepening a collaboration even as Samsung reported an operating profit for the first time.

Pfizer, struggling to build traction for its Remicade biosimilar in the U.S., has some new data it hopes can make a difference in building sales.

AbbVie took a big step toward putting investors’ minds at ease about aging blockbuster Humira, with better-than-expected third-quarter results.

Despite a cyberattack and a patent loss on a key drug, Merck & Co. beat Street earnings forecast for the third quarter and raised its forecast for the year.